Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia

References

• American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders (4th edn – text revision). Washington (DC): American Psychiatric Association.
   Google Scholar
• Andreassen OA, Jørgensen HA. 1994. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology. 116:517–522.
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jorgensen HA. 2000. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol. 61:525–541.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. 2008. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 69:1580–1588.
   PubMed Web of Science ®Google Scholar
• Bakker PR, Al Hadithy AFY, Amin N, van Duijn CM, van Os J, van Harten PN. 2012. Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study. PLoS One. 7:e50970.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 21:263–265.
   PubMed Web of Science ®Google Scholar
• Benzel I, Bansal A, Browning BL, Galwey NW, Maycox PR, McGinnis R, Smart D, St Clair D, Yates P, Purvis I. 2007. Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav Brain Funct. 3:31.
   PubMed Web of Science ®Google Scholar
• Carlsson T, Schindler FR, Hollerhage M, Depboylu C, Arias-Carrion O, Schnurrbusch S, Rosler TW, Wozny W, Schwall GP, Groebe K, et al. 2011. Systemic administration of neuregulin-1beta1 protects dopaminergic neurons in a mouse model of Parkinson’s disease. J Neurochem. 117:1066–1074.
   PubMed Web of Science ®Google Scholar
• Deng C, Pan B, Engel M, Huang XF. 2013. Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway. Psychopharmacology (Berl). 226:201–215.
   PubMed Web of Science ®Google Scholar
• Dudbridge F. 2008. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered. 66:87–98.
   PubMed Web of Science ®Google Scholar
• Gu Z, Jiang Q, Fu AK, Ip NY, Yan Z. 2005. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci. 25:4974–4984.
   PubMed Web of Science ®Google Scholar
• Gunne LM, Andren PE. 1993. An animal model for coexisting tardive dyskinesia and tardive Parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol. 16:90–95.
   PubMed Web of Science ®Google Scholar
• Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, Borgmann-Winter KE, Siegel SJ, et al. 2006. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 12:824–828.
   PubMed Web of Science ®Google Scholar
• Ivanova S, Loonen A, Pechlivanoglou P, Freidin M, Al Hadithy A, Rudikov E, Zhukova I, Govorin N, Sorokina V, Fedorenko O, et al. 2012. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry. 2:e67.
   PubMed Web of Science ®Google Scholar
• Kampman O, Anttila S, Illi A, Saarela M, Rontu R, Mattila KM, Leinonen E, Lehtimaki T. 2004. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport. 15:2517–2520.
   PubMed Web of Science ®Google Scholar
• Karbownik MS, Szemraj J, Wieteska L, Antczak A, Gorski P, Kowalczyk E, Pietras T. 2016. Antipsychotic drugs differentially affect mRNA expression of genes encoding the neuregulin 1-downstream ErbB4-PI3K pathway. Pharmacology. 98:4–12.
   PubMed Web of Science ®Google Scholar
• Kato T, Abe Y, Sotoyama H, Kakita A, Kominami R, Hirokawa S, Ozaki M, Takahashi H, Nawa H. 2011. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry. 16:307–320.
   PubMed Web of Science ®Google Scholar
• Kwon OB, Paredes D, Gonzalez CM, Neddens J, Hernandez L, Vullhorst D, Buonanno A. 2008. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc Natl Acad Sci USA. 105:15587–15592.
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Nurnberger JI. 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19:5444.
   PubMed Web of Science ®Google Scholar
• Lanning RK, Zai CC, Muller DJ. 2016. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 17:1339–1351.
   PubMed Web of Science ®Google Scholar
• Law AJ, Kleinman JE, Weinberger DR, Weickert CS. 2007. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet. 16:129–141.
   PubMed Web of Science ®Google Scholar
• Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR. 2006. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci USA. 103:6747–6752.
   PubMed Web of Science ®Google Scholar
• Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, Papaleo F, Straub RE, Huang W, Thomas CJ, Vakkalanka R, et al. 2012. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc Natl Acad Sci USA. 109:12165–12170.
   PubMed Web of Science ®Google Scholar
• Li J, Ji L. 2005. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb). 95:221–227.
   PubMed Web of Science ®Google Scholar
• Mei L, Xiong WC. 2008. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 9:437–452.
   PubMed Web of Science ®Google Scholar
• Müller DJ, Schulze T, Knapp M, Held T, Krauss H, Weber T, Ahle G, Maroldt A, Alfter D, Maier W, et al. 2001. Familial occurrence of tardive dyskinesia. Acta Psychiat Scand. 104:375–379.
   PubMed Web of Science ®Google Scholar
• Nyholt DR. 2004. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 74:765–769.
   PubMed Web of Science ®Google Scholar
• Pan B, Huang XF, Deng C. 2011. Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 35:924–930.
   PubMed Web of Science ®Google Scholar
• Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 39:486–487.
   PubMed Web of Science ®Google Scholar
• Stefansson H, et al. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 71:877–892.
   PubMed Web of Science ®Google Scholar
• Teo JT, Edwards MJ, Bhatia K. 2012. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 27:1205–1215.
   PubMed Web of Science ®Google Scholar
• Tomiyama K, O'Tuathaigh CM, O'Sullivan GJ, Kinsella A, Lai D, Harvey RP, Tighe O, Croke DT, Koshikawa N, Waddington JL. 2009. Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 ‘knockout’ mice. Prog Neuropsychopharmacol Biol Psychiatry. 33:330–333.
   PubMed Web of Science ®Google Scholar
• Yassa R, Ananth J. 1981. Familial tardive dyskinesia. Am J Psychiatry. 138:1618–1619.
   PubMed Web of Science ®Google Scholar
• Zai C, Tiwari A, Basile V, De Luca V, Muller D, King N, Voineskos A, Remington G, Meltzer H, Lieberman J, et al. 2009a. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J. 9:168–174.
   PubMed Web of Science ®Google Scholar
• Zai CC, De Luca V, Hwang RW, Voineskos A, Müller DJ, Remington G, Kennedy JL. 2007a. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry. 12:794–795.
   PubMed Web of Science ®Google Scholar
• Zai CC, Hwang RW, De Luca V, Muller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, et al. 2007b. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol. 10:639–651.
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, De Luca V, Muller DJ, Bulgin N, Hwang R, Zai GC, King N, Voineskos AN, Meltzer HY, et al. 2009b. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol. 19:317–328.
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, Muller DJ, De Luca V, Shinkai T, Shaikh S, Xingqun N, Sibony D, Voineskos AN, Meltzer HY, et al. 2010. The catechol-O-methyl-transferase gene in tardive dyskinesia. World J Biol Psychiatry. 11:803–812.
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, Mazzoco M, De Luca V, Muller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, et al. 2013. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatric Res. 47:1760–1765.
   PubMed Web of Science ®Google Scholar